
RS Oncology announces new preclinical data showing that RSO-021 can block and/or reverse the progression of aggressive mesotheliomas, improving drug availability
RS Oncology announces new preclinical data showing that RSO-021 can block and/or reverse the progression of aggressive mesotheliomas, improving drug availability RS Oncology , a clinical-stage biotechnology company developing innovative therapies to eliminate mesothelioma and other diseases, was part of a…